Medpace Holdings, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Medpace Holdings, Inc., a global clinical contract research organization (CRO), for the period ended March 31, 2026. The Company provides full-service Phase I-IV clinical development services to pharmaceutical, biotechnology, and medical device companies. As of March 31, 2026, the Company employed approximately 6,300 people across 46 countries.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue, Net | $706.6 million | $558.6 million |
| Net Income | $123.9 million | $114.6 million |
| Diluted EPS | $4.28 | $3.67 |
| Operating Cash Flow | $151.8 million | $125.8 million |
| Cash and Equivalents | $652.7 million | $441.4 million |
| Total Debt | $0 | $0 |
| Backlog | $2,929.2 million | $2,846.0 million |
Margins: Operating income was $141.5 million (20.0% margin). The effective income tax rate was 16.1% for Q1 2026, compared to 3.0% in Q1 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 26.5% year-over-year, driven by growth in Metabolic, Oncology, Central Nervous System, and AVAI therapeutic areas.
- Cost Structure: Total direct costs rose 34.2% to $510.3 million, primarily due to a $109.6 million increase in reimbursed out-of-pocket expenses and higher personnel costs. Conversely, Selling, General, and Administrative (SG&A) expenses decreased 17.2% to $47.9 million, largely due to a $11.9 million reduction in stock-based compensation.
- Profitability: Net income increased 8.1% despite a higher tax provision, aided by improved operating leverage and lower SG&A.
- Share Repurchases: The Company executed no share repurchases in Q1 2026, compared to $389.8 million in repurchases during Q1 2025. Remaining authorization stands at $821.7 million.
Outlook, Risks, and Contingencies
- Backlog: Backlog increased 2.9% to $2,929.2 million. Approximately $1.93 billion to $1.95 billion is expected to convert to revenue over the next 12 months.
- Liquidity: The Company maintains a strong liquidity position with $652.7 million in cash and a $10.0 million unsecured credit facility with no outstanding borrowings.
- Legal Proceedings: A class action complaint was filed on April 6, 2026, alleging violations of federal securities laws regarding the Company's book-to-bill ratio. The Company states no liability has been recognized as the potential loss is not currently probable or reasonably estimable.
- Related Party Transactions: Significant related party transactions exist, including leases for corporate headquarters owned by the CEO and clinical trial services provided to entities (LIB Therapeutics, CinRx) where executives serve on boards.
Investor Verification Checklist
- Verify the sustainability of the 26.5% revenue growth rate, specifically the contribution from reimbursed out-of-pocket expenses which fluctuate based on project timing.
- Monitor the impact of the April 2026 class action lawsuit regarding book-to-bill ratio disclosures on future stock price and potential legal costs.
- Assess the concentration of related party transactions, particularly the lease agreements with the CEO's entities and revenue from LIB Therapeutics and CinRx.
- Review the conversion rate of the $2.9 billion backlog into actual revenue over the next 12 months.
- Confirm the Company's strategy regarding capital allocation given the halt in share repurchases and the remaining $821.7 million authorization.